Analyses of survival and matched genotype and expression data from TCGA datasets indicated that MED12 expression can stratify the survival of individuals with BRCA2-mutant ovarian and bladder tumors: high MED12 expression trended towards increased survival, while low MED12 expression trended towards reduced survival (Figure 1H,I). This evidence concerns the gene MED12 and urinary bladder neoplasm.